Table 1. Demographics and clinical characteristics of COVID-19 patients

From: Longitudinal analysis of neutralizing antibodies against SARS-CoV-1 and different SARS-CoV-2 strains in breakthrough and unvaccinated COVID-19 patients in Thailand (2021-2022)

Characteristics

COVID-19 patientsa

(N = 111)

Demographics

Age in years, median (IQR)

53 (41–63)

Male, number, %

45 (40.5)

Female, number, %

66 (59.5)

Vaccination history, number, %

Unvaccinated

17 (15.3)

Homologous inactivated vaccine (1–2 doses)

10 (9.0)

Homologous viral vector vaccine (1–2 doses)

31 (27.9)

Homologous mRNA vaccine (2–3 doses)

4 (3.6)

Heterologous vaccine (2–5 doses) *

49 (44.1)

Pre-existing conditions, number, %

No underlying disease

47 (42.3)

Hypertension

35 (31.5)

Dyslipidemia

30 (27.0)

Diabetes mellitus

18 (16.2)

Chronic heart disease

8 (7.2)

BMI ≥ 30

20 (18.0)

Chronic hematologic disease

3 (2.7)

Asthma

4 (3.6)

Cancer

1 (0.9)

Rheumatologic disease

5 (4.5)

Day to enrollment, median (IQR)

Duration of hospital stay, day, median (IQR)

1 (0–2)

Unvaccinated patients

Vaccinated patients

10 (9–15)

8 (6–11)

Pneumonia

41 (36.9)

Organ involved and complications, N (%)

Lung

64 (57.7)

Liver

13 (11.7)

Kidney

5 (4.5)

Death

0 (0)

  1. *Heterologous vaccine regimens consist of combinations of 2–5 doses of inactivated, viral vector, and mRNA vaccines (see supplementary Table S1)
  2. a Neutralizing antibody data for 111 COVID-19 patients were partially obtained from a previously published dataset33.
Back to article page